NCT03520842View on ClinicalTrials.gov

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions
KRAS Gene MutationMetastatic Malignant Neoplasm in the BrainRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
DRUG

Methotrexate

Given PO

OTHER

Pharmacokinetic Study

Correlative studies

DRUG

Regorafenib

Given PO

Trial Locations (1)

94304

Stanford University School of Medicine, Palo Alto

All Listed Sponsors
lead

Stanford University

OTHER

NCT03520842 - Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter